Scarica l'app Stockscreener
3.20
0.31%
0.01
Dopo l'orario di chiusura:
3.22
0.02
+0.63%
Precedente Chiudi:
$3.19
Aprire:
$3.18
Volume 24 ore:
133.77K
Relative Volume:
0.98
Capitalizzazione di mercato:
$120.88M
Reddito:
-
Utile/perdita netta:
$-27.66M
Rapporto P/E:
-3.3684
EPS:
-0.95
Flusso di cassa netto:
$-24.36M
1 W Prestazione:
-10.86%
1M Prestazione:
-6.71%
6M Prestazione:
-41.39%
1 anno Prestazione:
+55.34%
Intervallo 1D:
$3.03
$3.50
Intervallo di 1 settimana:
$3.03
$3.61
Portata 52W:
$1.95
$5.885
Genelux Corp Stock (GNLX) Company Profile
Nome
Genelux Corp
Settore
Industria
Telefono
805-267-9889
Indirizzo
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Confronta GNLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.20 | 120.50M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-29 | Iniziato | Guggenheim | Buy |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-11-27 | Iniziato | H.C. Wainwright | Buy |
| 2023-09-12 | Iniziato | Maxim Group | Buy |
| 2023-02-15 | Iniziato | The Benchmark Company | Speculative Buy |
Genelux Corp Borsa (GNLX) Ultime notizie
Genelux Corporation stock daily chart insightsJuly 2025 Gainers & Consistent Income Trade Ideas - Newser
Applying Wyckoff theory to Genelux Corporation stockJuly 2025 Fed Impact & Technical Buy Zone Confirmations - Newser
Genelux Corporation stock trend forecastDay Trade & AI Forecasted Entry/Exit Points - Newser
Genelux Corporation stock prediction for this weekMarket Movement Recap & Low Risk Investment Opportunities - Newser
Is a relief rally coming for Genelux Corporation holdersRisk Management & Free Technical Confirmation Trade Alerts - Newser
Technical analysis overview for Genelux Corporation stock [2025 Geopolitical Influence]Free Safe Entry Trade Signal Reports - Newser
How Efficient Is Genelux Corporation at Controlling Operating Costs [July 2025 Analyst Calls]Smart Investment Allocation Tips - Newser
How sentiment analysis helps forecast Genelux CorporationMarket Activity Summary & Capital Protection Trade Alerts - Newser
Genelux Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Genelux Corp.’s Innovative Cancer Treatment Approach Earns Buy Rating - TipRanks
What to do if you’re stuck in Genelux CorporationFree Community Entry Consensus Trade Ideas - Newser
Advanced analytics toolkit walkthrough for Genelux CorporationWeekly Gain Forecast with Momentum Indicators - Newser
News impact scoring models applied to Genelux CorporationStock Entry Point Planner with Volume Spike - Newser
How to escape a deep drawdown in Genelux CorporationIntraday Signal Forecast for Fast Traders - Newser
Why Genelux Corporation stock attracts strong analyst attentionFree AI Driven Buy Alert Trade Blueprint - Newser
Promising Outlook for Genelux Corp. with Olvi-Vec Advancements and Strong Financial Position - TipRanks
Genelux Corp.'s Olvi-Vec: A Promising Oncology Treatment with a Buy Rating - AInvest
Genelux Corp expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments - TipRanks
Can trapped investors hope for a rebound in Genelux CorporationWealth Accumulation Outlook for Safe Investors - Newser
Genelux reports Q2 EPS (20c), consensus (22c) - TipRanks
Genelux Q2 Earnings Exceed Expectations with $0.20 GAAP EPS and $28.1M in Cash and Investments - AInvest
Genelux Q2 Earnings: Phase 3 Ovarian Cancer Trial On Track, 71% Success in Lung Cancer | GNLX Stock News - Stock Titan
Developing predictive dashboards with Genelux Corporation dataFree Daily Top Performing Stock Insights - Newser
Does Genelux Corporation show high probability of reboundAI Intraday Market Movement Prediction Tool - Newser
Building trade automation scripts for Genelux CorporationPattern Recognition Based Market Move Prediction - Newser
Genelux Corporation Stock Approaches Key Moving AverageSwing Trade Entry With Volume Triggers Released - beatles.ru
What are the latest earnings results for Genelux CorporationMarket Forecast Signals For Fast Growth - Jammu Links News
How Genelux Corporation stock performs during market volatilityCapital Growth Summary Over Five Years - Newser
How to use a screener to detect Genelux Corporation breakoutsDividend Strategy Summary With 10-Year Outlook - Newser
Genelux Corporation Added to High Probability Setup ListHigh Conviction Intraday Stock Signals Detected - metal.it
Does Genelux Corporation stock perform well during market downturnsAchieve unparalleled market performance - Jammu Links News
Using AI based signals to follow Genelux CorporationEarnings Report Summary with Market Impact - Newser
Is it the right time to buy Genelux Corporation stockGet alerts on the hottest market movers - Jammu Links News
What drives Genelux Corporation stock priceBreakthrough investment results - Autocar Professional
Genelux Corporation Stock Analysis and ForecastTriple returns potential - Autocar Professional
Genelux stock maintains Buy rating at H.C. Wainwright amid sector news - Investing.com India
Genelux stock maintains Buy rating at H.C. Wainwright amid sector news By Investing.com - Investing.com South Africa
Genelux Corp Azioni (GNLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):